Kalaris Therapeutics, Inc. (KLRS)
| Market Cap | 45.26M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -75.96M |
| Shares Out | 18.70M |
| EPS (ttm) | -10.39 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 34,763 |
| Open | 2.500 |
| Previous Close | 2.500 |
| Day's Range | 2.420 - 2.652 |
| 52-Week Range | 2.280 - 24.150 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | n/a |
| Earnings Date | Aug 15, 2025 |
About KLRS
Kalaris Therapeutics, Inc., a clinical-stage ophthalmology biotech company, engages in developing therapies for the treatment of neovascular retinal diseases. Kalaris Therapeutics, Inc. was formerly known as Theia Therapeutics, Inc. and changed its name to Kalaris Therapeutics, Inc. in May 2024. The company was incorporated in 2019 and is based in Palo Alto, California. [Read more]
Financial Performance
Financial StatementsNews
Kalaris to Present at Noble Capital Markets 2025 Emerging Growth Equity Conference
PALO ALTO, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercializatio...
Kalaris to Participate at Stifel Ophthalmology Forum
PALO ALTO, Calif., May 23, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization...
Kalaris Reports First Quarter 2025 Financial Results and Provides Business Highlights
Actively enrolling nAMD patients in a Phase 1 trial of TH103, a novel, differentiated anti-VEGF agent engineered to potentially provide longer-lasting and increased anti-VEGF activity to treat neovasc...
Kalaris Expands Board of Directors Appointing Leone Patterson as Chair of Audit Committee
Highly experienced biotech executive and board member will assist Kalaris in achieving its next phase of growth Highly experienced biotech executive and board member will assist Kalaris in achieving i...
Kalaris Announces Closing of Merger with AlloVir
Kalaris is focused on developing TH103, a novel, differentiated anti-VEGF agent engineered to potentially provide longer-lasting and increased anti-VEGF activity to treat neovascular and exudative dis...